Clinical Trials Directory

Trials / Completed

CompletedNCT01238835

PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)

Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (TransApical)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
220 (actual)
Sponsor
Edwards Lifesciences · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; "study valve"), the next generation Ascendra™ transapical delivery system, and crimper accessories.

Detailed description

Purpose: The purpose of this trial is to evaluate the acute safety and effectiveness of the SAPIEN XT™ study valve and next generation Ascendra™ delivery components. Follow-up Intervals: Subject data collection will include clinical information at baseline and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30 days, 6 month annually for 5 years.

Conditions

Interventions

TypeNameDescription
DEVICESAPIEN XT™ Transapical aortic valve replacementTranscatheter aortic valve implantation via the transapical approach

Timeline

Start date
2009-09-01
Primary completion
2011-02-01
Completion
2016-03-01
First posted
2010-11-11
Last updated
2020-11-02
Results posted
2020-11-02

Locations

20 sites across 4 countries: Austria, France, Germany, United Kingdom

Source: ClinicalTrials.gov record NCT01238835. Inclusion in this directory is not an endorsement.